Tokyo, July 30 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000057999) titled 'Investigation of Finerenone Treatment Effects and Safety' on July 30.
Study Type:
Observational
Primary Sponsor:
Institute - Meitetsu hospital
Condition:
Condition - Type 2 diabetes mellitus
Classification by malignancy - Others
Genomic information - NO
Objective:
Narrative objectives1 - The objective of this study is to evaluate the effectiveness and safety of finerenone in patients with type 2 diabetes mellitus and chronic kidney disease using real-world clinical data, as well as to investigate the impact of concomitant use of SGLT2 inhibitors and ACE inhibitors or ARBs on the effects of finerenone.
Basic objectives2 - Safety
Eligibility:
Age-lower limit - 18
years-old
<=
Age-upper limit - Not applicable
Gender - Male and Female
Key inclusion criteria - Patients treated at Meitetsu Hospital
Aged 18 years or older
Diagnosed with type 2 diabetes and chronic kidney disease and initiated on finerenone
Able to be followed for at least 3 months
Opt-out consent has been appropriately obtained
Key exclusion criteria - Patients with end-stage renal disease (on dialysis or eGFR <15 mL/min/1.73m)
Patients who discontinued finerenone within one month after initiation
Patients deemed inappropriate for inclusion by the attending physician
Target Size - 100
Recruitment Status:
Recruitment status - No longer recruiting
Date of protocol fixation - 2025 Year 03 Month 01 Day
Date of IRB - 2025 Year 04 Month 15 Day
Anticipated trial start date - 2025 Year 03 Month 01 Day
Last follow-up date - 2025 Year 03 Month 31 Day
To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000066300
Disclaimer: Curated by HT Syndication.
